Pfizer Ltd
₹5062.20
(-0.57%)
Wed, 11 Mar 2026, 05:58 am
Health Technology
Pharmaceuticals: Major
24.5KPfizer PB Ratio
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 38.60 | 21.73 | 5.68 | 4.66 | 20.79 | 21.65 | 19.42 | 6.29 | 17.08 | 101.70 | 26.80 | 25.71 | 27.77 | 35.41 | 36.17 | 41.57 | 32.50 | 25.40 | 34.80 | 23.86 |
| Price to book ratio | 7.14 | 5.70 | 2.97 | 1.55 | 2.86 | 3.14 | 2.75 | 1.87 | 5.73 | 5.17 | 3.78 | 3.58 | 3.73 | 5.04 | 5.42 | 8.64 | 6.95 | 4.94 | 5.34 | 4.34 |
| Price to sales ratio | 4.26 | 3.33 | 2.77 | 1.98 | 3.58 | 4.17 | 3.28 | 3.02 | 3.40 | 5.51 | 4.06 | 4.40 | 5.08 | 7.30 | 8.56 | 9.24 | 7.62 | 6.54 | 8.75 | 8.03 |
| Price to cash flow ratio | 24.58 | 17.27 | 38.66 | 4.79 | 20.89 | 22.39 | 33.88 | 47.01 | 16.34 | 66.83 | 20.34 | 21.22 | 23.71 | 69.53 | 39.79 | 44.10 | 28.04 | 37.19 | 49.82 | 22.93 |
| Enterprise value | 24.75B | 20.04B | 14.52B | 8.51B | 23.19B | 30.78B | 27.19B | 17.31B | 34.51B | 95.77B | 71.51B | 71.37B | 82.29B | 132.8B | 163.21B | 196.76B | 184.41B | 141.22B | 172.33B | 156.25B |
| Enterprise value to EBITDA ratio | 17.94 | 12.32 | 9.42 | 5.67 | 10.64 | 21.40 | 13.99 | 9.31 | 14.30 | 24.88 | 16.44 | 20.39 | 16.16 | 22.95 | 27.72 | 27.42 | 21.60 | 17.06 | 26.35 | 20.62 |
| Debt to equity ratio | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.04 | 0.04 | 0.06 | 0.04 | 0.03 | 0.03 |
| Return on equity % | 19.77 | 27.21 | 62.42 | 38.63 | 14.44 | 15.65 | 14.96 | 33.56 | 18.77 | 7.63 | 14.75 | 14.70 | 14.11 | 15.07 | 15.89 | 17.19 | 23.30 | 20.55 | 16.21 | 19.65 |
Pfizer Ltd Price to Book Ratio
The Pfizer Ltd Price to Book Ratio is a key financial metric used by investors to evaluate Pfizer Ltd's valuation, profitability, and overall financial performance. Tracking the Pfizer Ltd Price to Book Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Pfizer Ltd (NSE: PFIZER, BSE: 500680) is currently trading at ₹5062.20, with a market capitalization of ₹231.87B. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Pfizer Ltd Price to Book Ratio is essential for fundamental analysis.
Pfizer Ltd Price to Book Ratio Current Value
The current Pfizer Ltd Price to Book Ratio stands at 4.34.
The Pfizer Ltd Price to Book Ratio has declined compared to earlier levels, suggesting improved fundamentals or more attractive valuation.
Pfizer Ltd Price to Book Ratio Historical Trend
The Pfizer Ltd Price to Book Ratio has shown the following historical trend:
- 2024: 4.34
- 2023: 5.34
- 2022: 4.94
- 2021: 6.95
- 2020: 8.64
The decline in Pfizer Ltd Price to Book Ratio indicates improving financial efficiency or better earnings growth.
What Pfizer Ltd Price to Book Ratio Indicates for Investors
The Pfizer Ltd Price to Book Ratio plays a crucial role in understanding the company's financial health and valuation.
The P/B ratio shows how the market values company assets relative to book value.
Pfizer Ltd Price to Book Ratio Analysis Summary
The Pfizer Ltd Price to Book Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Pfizer Ltd Price to Book Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Pfizer Ltd Price to Book Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800